New Funding Backs Precision in mRNA Medicine

BreezeBio raises $60M to push precision mRNA delivery into the clinic, targeting diabetes and cancer with its NanoGalaxy platform

23 Mar 2026

BreezeBio, a South San Francisco-based biotechnology group, has raised $60mn in a Series B round to advance its mRNA delivery technology and move its lead therapy towards clinical testing.

The financing, completed on February 25, was co-led by Yuanta Investment and DSC Investment, with participation from more than a dozen institutional and strategic investors across the US and Asia. The round reflects rising investor interest in delivery systems designed to improve how genetic medicines reach specific tissues.

The company is developing NanoGalaxy, a platform based on engineered polymer nanoparticles that can transport mRNA and other genetic material to targeted cell types. Unlike lipid nanoparticles used in Covid-19 vaccines, BreezeBio’s particles are designed for repeated dosing and can be tuned to reach immune, cardiac, pulmonary and neurological tissues.

Proceeds from the funding will support the company’s first internal therapeutic programme, BRZ-101, an mRNA-based treatment for type 1 diabetes. The therapy aims to retrain the immune system to stop attacking insulin-producing cells. In preclinical studies in mice and non-human primates, BRZ-101 induced antigen-specific immune tolerance without broadly suppressing immune responses.

BreezeBio said it is advancing the programme into investigational new drug (IND)-enabling studies, with a first-in-human trial planned thereafter.

The company is also expanding its platform into oncology and in vivo cell therapy, where treatments are generated inside the patient’s body rather than delivered as manufactured cells. This approach has attracted growing interest from large pharmaceutical groups, with several recent acquisitions in the sector.

BreezeBio, previously known as GenEdit, has collaborated with Genentech, providing early validation of its delivery technology ahead of the latest fundraising.

The company’s shift from a delivery platform provider to a therapeutics developer reflects broader changes in the mRNA field, as groups seek to build pipelines beyond vaccines. Further progress will depend on clinical outcomes and the ability to demonstrate safety and repeat dosing in humans.